Projected Timeline for U.S. Cancer Vaccine Availability
Copilot said:
Key Milestones
- 2025: Phase 3 trials ongoing for leading candidates (e.g., Moderna/Merck mRNA‑4157).
- 2026: Phase 3 completion and data analysis.
- 2027: FDA review and potential approval for melanoma indication.
- 2028: Initial market launch for high-risk patients (likely melanoma first).
- 2029: Expanded indications (lung, bladder, renal) and wider consumer access.
No Comments
You must log on to comment.